Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adalimumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    468 result(s) found for: Adalimumab. Displaying page 1 of 24.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-002047-29 Sponsor Protocol Number: PI843_843_0080 Start Date*: 2021-07-29
    Sponsor Name:CHU Amiens Picardie
    Full Title: Comparison of azathioprine to methotrexate in combination therapy with adalimumab in Crohn’s Disease: an open-label randomized controlled trial
    Medical condition: crohn disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004918-18 Sponsor Protocol Number: OPTIMAP Start Date*: 2014-02-03
    Sponsor Name:Academic Medical Center
    Full Title: Optimising adalimumab treatment in psoriasis with concomitant methotrexate.
    Medical condition: psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001793-28 Sponsor Protocol Number: 371b Start Date*: 2019-11-05
    Sponsor Name:Reade
    Full Title: Adalimumab dose reduction aiming low serum concentration with control of disease activity (ADDORA-LOW) : a single blind, non-inferiority, randomised clinical trial
    Medical condition: Rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001594-14 Sponsor Protocol Number: FITC-ADA-CU-01 Start Date*: 2017-12-19
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Prospective, single-centre, open-label, one-arm clinical trial, phase I/IIa, to assess the safety and tolerability and to investigate the predictive power of FITC-Adalimumab, when topically applied...
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10066678 Acute ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004088-34 Sponsor Protocol Number: APHP180571 Start Date*: 2020-02-04
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP)
    Full Title: Effect of two injections of synchronized methotrexate with the first injection of Adalimumab to prevent anti-adalimumab immunization in spondyloarthritis
    Medical condition: adult patients with Axial Spondyloarthritis who have an indication for anti-TNF therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10028395 Musculoskeletal and connective tissue disorders SOC
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10071400 Axial spondyloarthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000352-29 Sponsor Protocol Number: B5381002 Start Date*: 2014-10-27
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06410293 AND ADALIMUMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ...
    Medical condition: RHEUMATOID ARTHRITIS
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) EE (Completed) LT (Completed) HU (Completed) GB (Completed) DE (Completed) ES (Completed) FR (Completed) BG (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003199-11 Sponsor Protocol Number: 2013-1 Start Date*: 2015-09-25
    Sponsor Name:GETAID - Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives
    Full Title: Changing the coUrse of cRohn's disease with an Early use of adalimumab: The CURE study.
    Medical condition: Crohn's disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003321-42 Sponsor Protocol Number: NL58948.091.16 Start Date*: 2017-01-18
    Sponsor Name:Radboud University Medical Centre
    Full Title: Lengthening Adalimumab Dosing Interval in quiescent Crohn’s disease patients: the LADI study.
    Medical condition: Crohn's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004967-30 Sponsor Protocol Number: RHMMED1596 Start Date*: 2019-04-30
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: IBD Reference and Biosimilar adalimumab CroSS over Study
    Medical condition: Crohn’s disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-003053-21 Sponsor Protocol Number: M16-560 Start Date*: 2019-06-27
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: Randomized, Double-Blind, Double-Dummy, Active Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Subjects with Moderate to Severe Rheumatoid Arth...
    Medical condition: Moderate to Severe Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001554-25 Sponsor Protocol Number: 371 Start Date*: 2019-10-29
    Sponsor Name:Reade
    Full Title: Adalimumab dose optimization in rheumatoid arthritis using therapeutic drug monitoring (ADDORA): multi-center single blinded randomized controlled trail
    Medical condition: Rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001918-42 Sponsor Protocol Number: TDM-ADA2019 Start Date*: 2020-04-22
    Sponsor Name:Ghent University Hospital
    Full Title: A non-inferiority study on dose reduction of adalimumab in psoriasis patients who are overtreated.
    Medical condition: Patients with moderate-to-severe psoriasis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001919-39 Sponsor Protocol Number: 48890 Start Date*: 2014-08-27
    Sponsor Name:Erasmus MC
    Full Title: Lengthening Adalimumab Dosing Interval in IBD patients in long term remission, the LADI study
    Medical condition: Inflammatory bowel disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001754-25 Sponsor Protocol Number: 371c Start Date*: 2019-11-25
    Sponsor Name:Reade
    Full Title: Using adalimumab serum concentration to choose a subsequent biological treatment in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): an open label randomized superiority ...
    Medical condition: rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001185-14 Sponsor Protocol Number: M04-724 Start Date*: 2005-06-01
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: Safety and Efficacy of Adalimumab in Patients with Psoriatic Arthritis (PsA)- An Open-Label, Multinational Study to Evaluate the Response to Every-Other Week Adalimumab When Added to Insufficient S...
    Medical condition: Psoriatic Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) SE (Completed) DK (Completed) GB (Completed) IE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004971-37 Sponsor Protocol Number: STRU-09-06 Start Date*: 2007-04-05
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St Thomas' NHS Foundation Trust
    Full Title: Adalimumab for psoriasis patients who are non-responders to etanercept: An open-label study
    Medical condition: psoriasis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003628-18 Sponsor Protocol Number: 000000 Start Date*: 2020-09-29
    Sponsor Name:University of Oxford, Clinical Trials and Research Governance
    Full Title: Adalimumab in COVID-19 to present respiratory failure in community care (AVID-CC): A randomised controlled trial
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    20.0 10022891 - Investigations 10070255 Coronavirus test positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2005-004826-21 Sponsor Protocol Number: M05-760 Start Date*: 2006-01-20
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing Spondylitis – An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therap...
    Medical condition: Active Ankylosing Spondylitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NO (Completed) DE (Completed) GB (Completed) SE (Completed) DK (Completed) IE (Completed) ES (Completed) BE (Completed) AT (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2019-003662-40 Sponsor Protocol Number: UKER-AMGEVITA-CED-NOVO-01 Start Date*: 2019-12-18
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Prospective, open-label, single-arm, single-center phase IV clinical trial to evaluate efficacy and safety of the adalimumab biosimilar Amgevita in subjects with moderate to severe active chronic i...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10021972 Inflammatory bowel disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004477-32 Sponsor Protocol Number: CAIN457F2366 Start Date*: 2017-03-29
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, active control, multicenter study to evaluate the efficacy at week 52 of subcutaneously administered secukinumab monotherapy compared with subcutaneously administered ad...
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) AT (Completed) GB (Completed) ES (Completed) GR (Completed) SK (Completed) DK (Completed) FI (Completed) NL (Completed) CZ (Completed) PT (Completed) HU (Completed) IS (Completed) BG (Completed) LT (Completed) LV (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 08:40:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA